Anzeige
Mehr »
Login
Sonntag, 07.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Bam Bam Resources und die Mega-Kupferlagerstätte in Teslas Hinterhof!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von PMLiVE

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
09.02.FDA considers new safety warnings for Pfizer's JAK inhibitor Xeljanz
09.02.EU orders another 300 million doses of Pfizer/BioNTech's COVID-19 vaccine
09.02.BMS and Exelixis' Opdivo/Cabometyx shows continued benefit in kidney cancer
09.02.Janssen's Erleada improves survival in certain advanced prostate cancer patients
08.02.FDA schedules meeting on 26 February to review J&J's one-dose COVID-19 vaccine
08.02.South Africa puts AZ/Oxford COVID-19 vaccine roll-out on hold
08.02.UK and CureVac to jointly develop vaccines against COVID-19 variants
08.02.FDA approves BMS' blood cancer CAR T therapy after delay
05.02.Merck's CEO Kenneth Frazier to retire after ten years in the role
05.02.Sanofi reports a profit in Q4 as Dupixent sales climb
05.02.Gilead's COVID-19 drug Veklury brought in almost $2bn in Q4
05.02.Rolling reviews of Novavax's COVID-19 vaccine begin across the globe
05.02.Roche's diagnostic business sales offer a bright spot in Q4
05.02.Medicinal data - what's next for IDMP?
04.02.Pfizer aims for $15bn in 2021 COVID-19 vaccine sales
04.02.UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen
04.02.GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines
04.02.Full impact of COVID-19 pandemic on cancer treatment unknown, according to GlobalData
04.02.Achieving an agile supply chain
03.02.AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
03.02.COVID-19 antibodies 'last at least six months' in most people
02.02.FDA approves new indication for Adamas' Gocovri in Parkinson's disease
02.02.UK vaccinations top nine million as concerns rise over South Africa variant
02.02.Transforming clinical trial data into a long-term asset
02.02.Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition